ID   HEXA_HUMAN              Reviewed;         529 AA.
AC   P06865; B4DKE7; E7ENH7; Q53HS8; Q6AI32;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   07-APR-2021, entry version 230.
DE   RecName: Full=Beta-hexosaminidase subunit alpha {ECO:0000305};
DE            EC=3.2.1.52 {ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671, ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901};
DE   AltName: Full=Beta-N-acetylhexosaminidase subunit alpha;
DE            Short=Hexosaminidase subunit A;
DE   AltName: Full=N-acetyl-beta-glucosaminidase subunit alpha;
DE   Flags: Precursor;
GN   Name=HEXA {ECO:0000312|HGNC:HGNC:4878};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-436.
RX   PubMed=2933746; DOI=10.1073/pnas.82.23.7830;
RA   Myerowitz R., Piekarz R., Neufeld E.F., Shows T.B., Suzuki K.;
RT   "Human beta-hexosaminidase alpha chain: coding sequence and homology with
RT   the beta chain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7830-7834(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-436.
RX   PubMed=2952641;
RA   Proia R.L., Soravia E.;
RT   "Organization of the gene encoding the human beta-hexosaminidase alpha-
RT   chain.";
RL   J. Biol. Chem. 262:5677-5681(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-436.
RX   PubMed=1833974;
RA   Triggs-Raine B.L., Akerman B.R., Clarke J.T.R., Gravel R.A.;
RT   "Sequence of DNA flanking the exons of the HEXA gene, and identification of
RT   mutations in Tay-Sachs disease.";
RL   Am. J. Hum. Genet. 49:1041-1054(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-436.
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   PSEUDODEFICIENCY TRP-249 AND VAL-436.
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-436.
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 23-32 AND 85-94, FUNCTION, CATALYTIC ACTIVITY,
RP   GLYCOSYLATION AT ASN-115; ASN-157 AND ASN-295, DISULFIDE BOND, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11707436; DOI=10.1074/jbc.m105457200;
RA   Hepbildikler S.T., Sandhoff R., Kolzer M., Proia R.L., Sandhoff K.;
RT   "Physiological substrates for human lysosomal beta -hexosaminidase S.";
RL   J. Biol. Chem. 277:2562-2572(2002).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 40-529 (ISOFORM 1), AND VARIANT VAL-436.
RX   PubMed=3013851;
RA   Korneluk R.G., Mahuran D.J., Neote K., Klavins M.H., O'Dowd B.F.,
RA   Tropak M., Willard H.F., Anderson M.-J., Lowden J.A., Gravel R.A.;
RT   "Isolation of cDNA clones coding for the alpha-subunit of human beta-
RT   hexosaminidase. Extensive homology between the alpha- and beta-subunits and
RT   studies on Tay-Sachs disease.";
RL   J. Biol. Chem. 261:8407-8413(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 89-99.
RX   PubMed=2965147;
RA   Mahuran D.J., Neote K., Klavins M.H., Leung A., Gravel R.A.;
RT   "Proteolytic processing of pro-alpha and pro-beta precursors from human
RT   beta-hexosaminidase. Generation of the mature alpha and beta a beta b
RT   subunits.";
RL   J. Biol. Chem. 263:4612-4618(1988).
RN   [12]
RP   PROTEIN SEQUENCE OF 96-105, AND STRUCTURE OF CARBOHYDRATES.
RX   PubMed=2971395; DOI=10.1021/bi00414a041;
RA   O'Dowd B.F., Cumming D.A., Gravel R.A., Mahuran D.J.;
RT   "Oligosaccharide structure and amino acid sequence of the major
RT   glycopeptides of mature human beta-hexosaminidase.";
RL   Biochemistry 27:5216-5226(1988).
RN   [13]
RP   GLYCOSYLATION AT ASN-115; ASN-157 AND ASN-295, AND MUTAGENESIS OF ASN-115;
RP   ASN-157 AND ASN-295.
RX   PubMed=1533633;
RA   Weitz G., Proia R.L.;
RT   "Analysis of the glycosylation and phosphorylation of the alpha-subunit of
RT   the lysosomal enzyme, beta-hexosaminidase A, by site-directed
RT   mutagenesis.";
RL   J. Biol. Chem. 267:10039-10044(1992).
RN   [14]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=8123671; DOI=10.1016/0304-4165(94)90118-x;
RA   Novak A., Callahan J.W., Lowden J.A.;
RT   "Classification of disorders of GM2 ganglioside hydrolysis using 3H-GM2 as
RT   substrate.";
RL   Biochim. Biophys. Acta 1199:215-223(1994).
RN   [15]
RP   CATALYTIC ACTIVITY, FUNCTION, AND SUBUNIT.
RX   PubMed=8672428; DOI=10.1021/bi9524575;
RA   Hou Y., Tse R., Mahuran D.J.;
RT   "Direct determination of the substrate specificity of the alpha-active site
RT   in heterodimeric beta-hexosaminidase A.";
RL   Biochemistry 35:3963-3969(1996).
RN   [16]
RP   ACTIVE SITES.
RX   PubMed=8652542; DOI=10.1021/bi960246+;
RA   Tse R., Vavougios G., Hou Y., Mahuran D.J.;
RT   "Identification of an active acidic residue in the catalytic site of beta-
RT   hexosaminidase.";
RL   Biochemistry 35:7599-7607(1996).
RN   [17]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=9694901; DOI=10.1074/jbc.273.33.21386;
RA   Hou Y., McInnes B., Hinek A., Karpati G., Mahuran D.;
RT   "A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A
RT   inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic
RT   Sandhoff disease.";
RL   J. Biol. Chem. 273:21386-21392(1998).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-157 AND ASN-295.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [21]
RP   3D-STRUCTURE MODELING.
RX   PubMed=8673609; DOI=10.1038/nsb0796-638;
RA   Tews I., Perrakis A., Oppenheim A., Dauter Z., Wilson K.S., Vorgias C.E.;
RT   "Bacterial chitobiase structure provides insight into catalytic mechanism
RT   and the basis of Tay-Sachs disease.";
RL   Nat. Struct. Biol. 3:638-648(1996).
RN   [22]
RP   REVIEW ON VARIANTS.
RX   PubMed=1825792; DOI=10.1016/0925-4439(91)90044-a;
RA   Mahuran D.J.;
RT   "The biochemistry of HEXA and HEXB gene mutations causing GM2
RT   gangliosidosis.";
RL   Biochim. Biophys. Acta 1096:87-94(1991).
RN   [23]
RP   REVIEW ON VARIANTS.
RX   PubMed=9090523;
RX   DOI=10.1002/(sici)1098-1004(1997)9:3<195::aid-humu1>3.0.co;2-7;
RA   Myerowitz R.;
RT   "Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A
RT   gene.";
RL   Hum. Mutat. 9:195-208(1997).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 23-529 IN COMPLEX WITH HEXB,
RP   GLYCOSYLATION AT ASN-115; ASN-157 AND ASN-295, DISULFIDE BONDS, AND
RP   SUBUNIT.
RX   PubMed=16698036; DOI=10.1016/j.jmb.2006.04.004;
RA   Lemieux M.J., Mark B.L., Cherney M.M., Withers S.G., Mahuran D.J.,
RA   James M.N.;
RT   "Crystallographic structure of human beta-hexosaminidase A: interpretation
RT   of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.";
RL   J. Mol. Biol. 359:913-929(2006).
RN   [25]
RP   VARIANT GM2G1 LYS-482.
RX   PubMed=2970528; DOI=10.1111/j.1471-4159.1988.tb01836.x;
RA   Nakano T., Muscillo M., Ohno K., Hoffman A.J., Suzuki K.;
RT   "A point mutation in the coding sequence of the beta-hexosaminidase alpha
RT   gene results in defective processing of the enzyme protein in an unusual
RT   GM2-gangliosidosis variant.";
RL   J. Neurochem. 51:984-987(1988).
RN   [26]
RP   VARIANT GM2G1 SER-269.
RX   PubMed=2522679; DOI=10.1126/science.2522679;
RA   Navon R., Proia R.L.;
RT   "The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult
RT   form of Tay-Sachs disease.";
RL   Science 243:1471-1474(1989).
RN   [27]
RP   VARIANT GM2G1 CYS-420.
RX   PubMed=2144098;
RA   Tanaka A., Punnett H.H., Suzuki K.;
RT   "A new point mutation in the beta-hexosaminidase alpha subunit gene
RT   responsible for infantile Tay-Sachs disease in a non-Jewish Caucasian
RT   patient (a Kpn mutant).";
RL   Am. J. Hum. Genet. 47:568-574(1990).
RN   [28]
RP   VARIANT GM2G1 HIS-504, AND CHARACTERIZATION OF VARIANT GM2G1 HIS-504.
RX   PubMed=2140574;
RA   Paw B.H., Moskowitz S.M., Uhrhammer N., Wright N., Kaback M.M.,
RA   Neufeld E.F.;
RT   "Juvenile GM2 gangliosidosis caused by substitution of histidine for
RT   arginine at position 499 or 504 of the alpha-subunit of beta-
RT   hexosaminidase.";
RL   J. Biol. Chem. 265:9452-9457(1990).
RN   [29]
RP   VARIANTS GM2G1 PHE-210 AND CYS-504.
RX   PubMed=1837283; DOI=10.1016/0888-7543(91)90109-r;
RA   Akli S., Lacorte J.-M., Poenaru L., Khan A.;
RT   "Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of
RT   PCR-amplified cDNA fragments.";
RL   Genomics 11:124-134(1991).
RN   [30]
RP   VARIANT GM2G1 GLY-320 DEL, AND VARIANTS ASP-399 AND VAL-436.
RX   PubMed=1532289;
RA   Mules E.H., Hayflick S., Miller C.S., Reynolds L.W., Thomas G.H.;
RT   "Six novel deleterious and three neutral mutations in the gene encoding the
RT   alpha-subunit of hexosaminidase A in non-Jewish individuals.";
RL   Am. J. Hum. Genet. 50:834-841(1992).
RN   [31]
RP   VARIANT PSEUDODEFICIENCY TRP-247.
RX   PubMed=1384323;
RA   Triggs-Raine B.L., Mules E.H., Kaback M.M., Lim-Steele J.S.T.,
RA   Dowling C.E., Akerman B.R., Natowicz M.R., Grebner E.E., Navon R.,
RA   Welch J.P., Greenberg C.R., Thomas G.H., Gravel R.A.;
RT   "A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers:
RT   implications for carrier screening.";
RL   Am. J. Hum. Genet. 51:793-801(1992).
RN   [32]
RP   VARIANTS GM2G1 TRP-170 AND HIS-258.
RX   PubMed=1302612; DOI=10.1093/hmg/1.9.759;
RA   Fernandes M., Kaplan F., Natowicz M., Prence E., Kolodny E., Kaback M.,
RA   Hechtman P.;
RT   "A new Tay-Sachs disease B1 allele in exon 7 in two compound heterozygotes
RT   each with a second novel mutation.";
RL   Hum. Mol. Genet. 1:759-761(1992).
RN   [33]
RP   VARIANT GM2G1 ASP-250.
RX   PubMed=1301189; DOI=10.1002/humu.1380010106;
RA   Trop I., Kaplan F., Brown C., Mahuran D., Hechtman P.;
RT   "A glycine250--> aspartate substitution in the alpha-subunit of
RT   hexosaminidase A causes juvenile-onset Tay-Sachs disease in a Lebanese-
RT   Canadian family.";
RL   Hum. Mutat. 1:35-39(1992).
RN   [34]
RP   VARIANT GM2G1 ARG-485.
RX   PubMed=1301190; DOI=10.1002/humu.1380010107;
RA   Akalin N., Shi H.-P., Vavougios G., Hechtman P., Lo W., Scriver C.R.,
RA   Mahuran D., Kaplan F.;
RT   "Novel Tay-Sachs disease mutations from China.";
RL   Hum. Mutat. 1:40-46(1992).
RN   [35]
RP   VARIANT PSEUDODEFICIENCY TRP-249.
RX   PubMed=7902672;
RA   Cao Z., Natowicz M.R., Kaback M.M., Lim-Steele J.S.T., Prence E.M.,
RA   Brown D., Chabot T., Triggs-Raine B.L.;
RT   "A second mutation associated with apparent beta-hexosaminidase A
RT   pseudodeficiency: identification and frequency estimation.";
RL   Am. J. Hum. Genet. 53:1198-1205(1993).
RN   [36]
RP   VARIANTS GM2G1.
RX   PubMed=8490625; DOI=10.1093/hmg/2.1.61;
RA   Akli S., Chomel J.-C., Lacorte J.-M., Bachner L., Poenaru A., Poenaru L.;
RT   "Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients.";
RL   Hum. Mol. Genet. 2:61-67(1993).
RN   [37]
RP   VARIANT GM2G1 SER-25.
RX   PubMed=8445615; DOI=10.1136/jmg.30.2.123;
RA   Harmon D.L., Gardner-Medwin D., Stirling J.L.;
RT   "Two new mutations in a late infantile Tay-Sachs patient are both in exon 1
RT   of the beta-hexosaminidase alpha subunit gene.";
RL   J. Med. Genet. 30:123-128(1993).
RN   [38]
RP   VARIANTS GM2G1 PHE-335 AND 347-ASP--GLU-352 DEL.
RX   PubMed=7951261; DOI=10.1002/humu.1380040112;
RA   Tomczak J., Grebner E.E.;
RT   "Three novel beta-hexosaminidase A mutations in obligate carriers of Tay-
RT   Sachs disease.";
RL   Hum. Mutat. 4:71-72(1994).
RN   [39]
RP   VARIANTS GM2G1 TYR-458 AND GLN-484.
RX   PubMed=7837766; DOI=10.1007/bf00711597;
RA   Tanaka A., Sakazaki H., Murakami H., Isshiki G., Suzuki K.;
RT   "Molecular genetics of Tay-Sachs disease in Japan.";
RL   J. Inherit. Metab. Dis. 17:593-600(1994).
RN   [40]
RP   VARIANTS GM2G1 SER-196 AND SER-250.
RX   PubMed=7717398;
RA   Triggs-Raine B.L., Richard M., Wasel N., Prence E.M., Natowicz M.R.;
RT   "Mutational analyses of Tay-Sachs disease: studies on Tay-Sachs carriers of
RT   French Canadian background living in New England.";
RL   Am. J. Hum. Genet. 56:870-879(1995).
RN   [41]
RP   VARIANT GM2G1 GLY-166.
RX   PubMed=8581357; DOI=10.1006/bmme.1995.1018;
RA   Peleg L., Meltzer F., Karpati M., Goldman B.;
RT   "GM2 gangliosidosis B1 variant: biochemical and molecular characterization
RT   of hexosaminidase A.";
RL   Biochem. Mol. Med. 54:126-132(1995).
RN   [42]
RP   VARIANT GM2G1 MET-391.
RX   PubMed=7898712; DOI=10.1212/wnl.45.3.539;
RA   Navon R., Khosravi R., Korczyn T., Masson M., Sonnino S., Fardeau M.,
RA   Eymard B., Lefevre N., Turpin J.C., Rondot P.;
RT   "A new mutation in the HEXA gene associated with a spinal muscular atrophy
RT   phenotype.";
RL   Neurology 45:539-543(1995).
RN   [43]
RP   VARIANT GM2G1 HIS-180.
RX   PubMed=8757036; DOI=10.1212/wnl.47.2.547;
RA   de Gasperi R., Gama Sosa M.A., Battistini S., Yeretsian J., Raghavan S.,
RA   Zelnik N., Leshinsky E., Kolodny E.H.;
RT   "Late-onset GM2 gangliosidosis: Ashkenazi Jewish family with an exon 5
RT   mutation (Tyr180-->His) in the Hex A alpha-chain gene.";
RL   Neurology 47:547-552(1996).
RN   [44]
RP   VARIANTS GM2G1 PHE-127; PHE-226; ASP-269 AND VAL-314.
RX   PubMed=9150157;
RA   Akerman B.R., Natowicz M.R., Kaback M.M., Loyer M., Campeau E.,
RA   Gravel R.A.;
RT   "Novel mutations and DNA-based screening in non-Jewish carriers of Tay-
RT   Sachs disease.";
RL   Am. J. Hum. Genet. 60:1099-1106(1997).
RN   [45]
RP   VARIANTS GM2G1 GLN-170; PHE-304 DEL AND LYS-482.
RX   PubMed=9338583;
RX   DOI=10.1002/(sici)1098-1004(1997)10:4<295::aid-humu5>3.0.co;2-g;
RA   Kaufman M., Grinshpun-Cohen J., Karpati M., Peleg L., Goldman B.,
RA   Akstein E., Adam A., Navon R.;
RT   "Tay-Sachs disease and HEXA mutations among Moroccan Jews.";
RL   Hum. Mutat. 10:295-300(1997).
RN   [46]
RP   VARIANT GM2G1 ARG-455.
RX   PubMed=9375850;
RX   DOI=10.1002/(sici)1098-1004(1997)10:5<359::aid-humu4>3.0.co;2-a;
RA   Ribeiro M.G., Pinto R.A., Suzuki K., Sa Miranda M.C.;
RT   "Two novel (1334delC and 1363G to A, G455R) mutations in exon 12 of the
RT   beta-hexosaminidase alpha-chain gene in two Portuguese patients.";
RL   Hum. Mutat. 10:359-360(1997).
RN   [47]
RP   VARIANT GM2G1 PRO-279.
RX   PubMed=9401008;
RX   DOI=10.1002/(sici)1098-1004(1997)10:6<451::aid-humu6>3.0.co;2-g;
RA   Drucker L., Hemli J.A., Navon R.;
RT   "Two mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs
RT   disease.";
RL   Hum. Mutat. 10:451-457(1997).
RN   [48]
RP   VARIANT GM2G1 CYS-474.
RX   PubMed=9603435;
RX   DOI=10.1002/(sici)1098-1004(1998)11:6<432::aid-humu3>3.0.co;2-z;
RA   Petroulakis E., Cao Z., Clarke J.T.R., Mahuran D.J., Lee G.,
RA   Triggs-Raine B.;
RT   "W474C amino acid substitution affects early processing of the alpha-
RT   subunit of beta-hexosaminidase A and is associated with subacute G(M2)
RT   gangliosidosis.";
RL   Hum. Mutat. 11:432-442(1998).
RN   [49]
RP   VARIANTS GM2G1 LEU-252; SER-295; CYS-420; CYS-499 AND HIS-499.
RX   PubMed=14566483; DOI=10.1007/s10038-003-0080-9;
RA   Tanaka A., Hoang L.T., Nishi Y., Maniwa S., Oka M., Yamano T.;
RT   "Different attenuated phenotypes of GM2 gangliosidosis variant B in
RT   Japanese patients with HEXA mutations at codon 499, and five novel
RT   mutations responsible for infantile acute form.";
RL   J. Hum. Genet. 48:571-574(2003).
RN   [50]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-436, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [51]
RP   VARIANTS GM2G1 LYS-114; TRP-170; ASN-322; TYR-322; PRO-393; VAL-462 AND
RP   ARG-478.
RX   PubMed=22723944; DOI=10.1371/journal.pone.0039122;
RA   Mistri M., Tamhankar P.M., Sheth F., Sanghavi D., Kondurkar P., Patil S.,
RA   Idicula-Thomas S., Gupta S., Sheth J.;
RT   "Identification of novel mutations in HEXA gene in children affected with
RT   Tay Sachs disease from India.";
RL   PLoS ONE 7:E39122-E39122(2012).
RN   [52]
RP   CHARACTERIZATION OF VARIANTS GM2G1 SER-269 AND LYS-482.
RX   PubMed=27682588; DOI=10.1091/mbc.e16-01-0012;
RA   Dersh D., Iwamoto Y., Argon Y.;
RT   "Tay Sachs disease mutations in HEXA target the alpha chain of
RT   hexosaminidase A to ER-associated degradation.";
RL   Mol. Biol. Cell 27:3813-3827(2016).
CC   -!- FUNCTION: Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or
CC       sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the
CC       oligosaccharide moieties from proteins and neutral glycolipids, or from
CC       certain mucopolysaccharides (PubMed:11707436, PubMed:9694901,
CC       PubMed:8672428, PubMed:8123671). The isozyme S is as active as the
CC       isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-
CC       sulfate trisaccharide (C6S-3), and the dermatan sulfate
CC       pentasaccharide, and the sulfated glycosphingolipid SM2
CC       (PubMed:11707436). The isozyme B does not hydrolyze each of these
CC       substrates, however hydrolyzes efficiently neutral oligosaccharide
CC       (PubMed:11707436). Only the isozyme A is responsible for the
CC       degradation of GM2 gangliosides in the presence of GM2A
CC       (PubMed:9694901, PubMed:8672428, PubMed:8123671).
CC       {ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671,
CC       ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Hydrolysis of terminal non-reducing N-acetyl-D-hexosamine
CC         residues in N-acetyl-beta-D-hexosaminides.; EC=3.2.1.52;
CC         Evidence={ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671,
CC         ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-3-
CC         sulfogalactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide = a beta-D-
CC         3-sulfogalactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide + N-
CC         acetyl-beta-D-galactosamine; Xref=Rhea:RHEA:48276, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:28497, ChEBI:CHEBI:90163, ChEBI:CHEBI:90164;
CC         Evidence={ECO:0000269|PubMed:11707436};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48277;
CC         Evidence={ECO:0000305|PubMed:11707436};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ganglioside GM2 (d18:1(4E)) + H2O = ganglioside GM3
CC         (d18:1(4E)) + N-acetyl-beta-D-galactosamine; Xref=Rhea:RHEA:47940,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:28497, ChEBI:CHEBI:60065,
CC         ChEBI:CHEBI:71502; Evidence={ECO:0000269|PubMed:8123671,
CC         ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47941;
CC         Evidence={ECO:0000305|PubMed:9694901};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ganglioside GM2 + H2O = ganglioside GM3 + N-acetyl-beta-D-
CC         galactosamine; Xref=Rhea:RHEA:47968, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:28497, ChEBI:CHEBI:79210, ChEBI:CHEBI:79218;
CC         Evidence={ECO:0000269|PubMed:8123671, ECO:0000269|PubMed:8672428,
CC         ECO:0000269|PubMed:9694901};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47969;
CC         Evidence={ECO:0000305|PubMed:9694901};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=beta-D-GalNAc-(1->4)-alpha-L-IdoA-(1->3)-beta-D-GalNAc-4-
CC         sulfate-(1->4)-alpha-L-IdoA-(1->3)-D-GalNAc-4-sulfate + H2O = alpha-
CC         L-IdoA-(1->3)-beta-D-GalNAc-4-sulfate-(1->4)-alpha-L-IdoA-(1->3)-D-
CC         GalNAc-4-sulfate + N-acetyl-D-galactosamine; Xref=Rhea:RHEA:64372,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:28037, ChEBI:CHEBI:152565,
CC         ChEBI:CHEBI:152566; Evidence={ECO:0000269|PubMed:11707436};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64373;
CC         Evidence={ECO:0000305|PubMed:11707436};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-acetyl-beta-D-6-sulfogalactosaminyl-(1->4)-alpha-L-
CC         iduronyl-(1->3)-N-acetyl-D-6-sulfogalactosamine = alpha-L-iduronyl-
CC         (1->3)-N-acetyl-D-6-sulfogalactosamine + N-acetyl-D-6-
CC         sulfogalactosamine; Xref=Rhea:RHEA:64384, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:152567, ChEBI:CHEBI:152568, ChEBI:CHEBI:153064;
CC         Evidence={ECO:0000269|PubMed:11707436};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64385;
CC         Evidence={ECO:0000305|PubMed:11707436};
CC   -!- ACTIVITY REGULATION: Addition of GM2A stimulates the hydrolysis of
CC       sulfated glycosphingolipid SM2 and the ganglioside GM2.
CC       {ECO:0000269|PubMed:11707436}.
CC   -!- SUBUNIT: There are 3 beta-hexosaminidase isozymes: isozyme A
CC       (hexosaminidase A) is an heterodimer composed of one subunit alpha and
CC       one subunit beta (chain A and B); isozyme B (hexosaminidase B) is an
CC       homodimer of two beta subunits (two chains A and B); isozyme S
CC       (hexosaminidase S) is a homodimer of two alpha subunits
CC       (PubMed:16698036). The composition of the dimer (isozyme A versus
CC       isozyme S) has a significant effect on the substrate specificity of the
CC       alpha subunit active site (PubMed:8672428).
CC       {ECO:0000269|PubMed:16698036, ECO:0000269|PubMed:8672428}.
CC   -!- INTERACTION:
CC       P06865; P07686: HEXB; NbExp=3; IntAct=EBI-723519, EBI-7133736;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P06865-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P06865-2; Sequence=VSP_056657, VSP_056658, VSP_056659;
CC   -!- PTM: N-linked glycan at Asn-115 consists of Man(3)-GlcNAc(2)
CC       (PubMed:1533633, PubMed:16698036, PubMed:19159218) (Probable). N-linked
CC       glycan at Asn-157 consists of either GlcNAc or GlcNAc(2)-Man(7-9). N-
CC       linked glycan at Asn-295 consists of either GlcNAc, GlcNAc-Fuc, or
CC       GlcNAc(2)-Man(4) (Probable). {ECO:0000269|PubMed:1533633,
CC       ECO:0000269|PubMed:16698036, ECO:0000269|PubMed:19159218,
CC       ECO:0000305|PubMed:11707436}.
CC   -!- DISEASE: GM2-gangliosidosis 1 (GM2G1) [MIM:272800]: An autosomal
CC       recessive lysosomal storage disease marked by the accumulation of GM2
CC       gangliosides in the neuronal cells. It is characterized by GM2
CC       gangliosides accumulation in the absence of HEXA activity, leading to
CC       neurodegeneration and, in the infantile form, death in early childhood.
CC       It exists in several forms: infantile (most common and most severe),
CC       juvenile and adult (late-onset). {ECO:0000269|PubMed:1301189,
CC       ECO:0000269|PubMed:1301190, ECO:0000269|PubMed:1302612,
CC       ECO:0000269|PubMed:14566483, ECO:0000269|PubMed:1532289,
CC       ECO:0000269|PubMed:1837283, ECO:0000269|PubMed:2140574,
CC       ECO:0000269|PubMed:2144098, ECO:0000269|PubMed:22723944,
CC       ECO:0000269|PubMed:2522679, ECO:0000269|PubMed:27682588,
CC       ECO:0000269|PubMed:2970528, ECO:0000269|PubMed:7717398,
CC       ECO:0000269|PubMed:7837766, ECO:0000269|PubMed:7898712,
CC       ECO:0000269|PubMed:7951261, ECO:0000269|PubMed:8445615,
CC       ECO:0000269|PubMed:8490625, ECO:0000269|PubMed:8581357,
CC       ECO:0000269|PubMed:8757036, ECO:0000269|PubMed:9150157,
CC       ECO:0000269|PubMed:9338583, ECO:0000269|PubMed:9375850,
CC       ECO:0000269|PubMed:9401008, ECO:0000269|PubMed:9603435}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 20 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M16424; AAB00965.1; -; Genomic_DNA.
DR   EMBL; M16411; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16412; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16413; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16414; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16415; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16416; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16417; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16418; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16419; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16420; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16421; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16422; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; M16423; AAB00965.1; JOINED; Genomic_DNA.
DR   EMBL; S62076; AAD13932.1; -; Genomic_DNA.
DR   EMBL; S62047; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62049; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62051; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62053; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62055; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62057; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62059; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62061; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62063; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62066; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62068; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62070; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; S62072; AAD13932.1; JOINED; Genomic_DNA.
DR   EMBL; AK296528; BAG59159.1; -; mRNA.
DR   EMBL; AK222502; BAD96222.1; -; mRNA.
DR   EMBL; CR627386; CAH10482.1; -; mRNA.
DR   EMBL; AC009690; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC018927; AAH18927.1; -; mRNA.
DR   EMBL; BC084537; AAH84537.1; -; mRNA.
DR   EMBL; M13520; AAA51827.1; -; mRNA.
DR   CCDS; CCDS10243.1; -. [P06865-1]
DR   PIR; A23561; AOHUBA.
DR   RefSeq; NP_000511.2; NM_000520.5. [P06865-1]
DR   RefSeq; NP_001305754.1; NM_001318825.1.
DR   PDB; 1QBC; Model; -; A=109-529.
DR   PDB; 2GJX; X-ray; 2.80 A; A/D/E/H=23-529.
DR   PDB; 2GK1; X-ray; 3.25 A; A/C/E/G=23-529.
DR   PDBsum; 1QBC; -.
DR   PDBsum; 2GJX; -.
DR   PDBsum; 2GK1; -.
DR   SMR; P06865; -.
DR   BioGRID; 109322; 52.
DR   ComplexPortal; CPX-502; Beta-hexosaminidase A complex.
DR   ComplexPortal; CPX-687; Beta-hexosaminidase S complex.
DR   CORUM; P06865; -.
DR   IntAct; P06865; 17.
DR   STRING; 9606.ENSP00000268097; -.
DR   BindingDB; P06865; -.
DR   ChEMBL; CHEMBL1250415; -.
DR   DrugCentral; P06865; -.
DR   SwissLipids; SLP:000001416; -. [P06865-1]
DR   CAZy; GH20; Glycoside Hydrolase Family 20.
DR   GlyConnect; 1038; 8 N-Linked glycans (1 site).
DR   GlyGen; P06865; 4 sites.
DR   iPTMnet; P06865; -.
DR   PhosphoSitePlus; P06865; -.
DR   SwissPalm; P06865; -.
DR   BioMuta; HEXA; -.
DR   DMDM; 311033393; -.
DR   EPD; P06865; -.
DR   jPOST; P06865; -.
DR   MassIVE; P06865; -.
DR   MaxQB; P06865; -.
DR   PaxDb; P06865; -.
DR   PeptideAtlas; P06865; -.
DR   PRIDE; P06865; -.
DR   ProteomicsDB; 4455; -.
DR   ProteomicsDB; 51937; -. [P06865-1]
DR   Antibodypedia; 26658; 485 antibodies.
DR   DNASU; 3073; -.
DR   Ensembl; ENST00000268097; ENSP00000268097; ENSG00000213614. [P06865-1]
DR   GeneID; 3073; -.
DR   KEGG; hsa:3073; -.
DR   UCSC; uc002aun.5; human. [P06865-1]
DR   CTD; 3073; -.
DR   DisGeNET; 3073; -.
DR   GeneCards; HEXA; -.
DR   GeneReviews; HEXA; -.
DR   HGNC; HGNC:4878; HEXA.
DR   HPA; ENSG00000213614; Low tissue specificity.
DR   MalaCards; HEXA; -.
DR   MIM; 272800; phenotype.
DR   MIM; 606869; gene.
DR   neXtProt; NX_P06865; -.
DR   OpenTargets; ENSG00000213614; -.
DR   Orphanet; 309192; Tay-Sachs disease, B variant, adult form.
DR   Orphanet; 309178; Tay-Sachs disease, B variant, infantile form.
DR   Orphanet; 309185; Tay-Sachs disease, B variant, juvenile form.
DR   Orphanet; 309239; Tay-Sachs disease, B1 variant.
DR   PharmGKB; PA29256; -.
DR   VEuPathDB; HostDB:ENSG00000213614.9; -.
DR   eggNOG; KOG2499; Eukaryota.
DR   GeneTree; ENSGT00390000008107; -.
DR   InParanoid; P06865; -.
DR   OrthoDB; 545162at2759; -.
DR   PhylomeDB; P06865; -.
DR   TreeFam; TF313036; -.
DR   BioCyc; MetaCyc:ENSG00000140495-MONOMER; -.
DR   BRENDA; 3.2.1.169; 2681.
DR   PathwayCommons; P06865; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-2022857; Keratan sulfate degradation.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-2160916; Hyaluronan uptake and degradation.
DR   Reactome; R-HSA-3656234; Defective HEXA causes GM2G1.
DR   SABIO-RK; P06865; -.
DR   BioGRID-ORCS; 3073; 5 hits in 994 CRISPR screens.
DR   ChiTaRS; HEXA; human.
DR   EvolutionaryTrace; P06865; -.
DR   GeneWiki; HEXA; -.
DR   GenomeRNAi; 3073; -.
DR   Pharos; P06865; Tchem.
DR   PRO; PR:P06865; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P06865; protein.
DR   Bgee; ENSG00000213614; Expressed in tendon of biceps brachii and 238 other tissues.
DR   ExpressionAtlas; P06865; baseline and differential.
DR   Genevisible; P06865; HS.
DR   GO; GO:0042582; C:azurophil granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004563; F:beta-N-acetylhexosaminidase activity; IDA:UniProtKB.
DR   GO; GO:0102148; F:N-acetyl-beta-D-galactosaminidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:MGI.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0030207; P:chondroitin sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0006689; P:ganglioside catabolic process; IDA:UniProtKB.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0030214; P:hyaluronan catabolic process; TAS:Reactome.
DR   GO; GO:0042340; P:keratan sulfate catabolic process; TAS:Reactome.
DR   Gene3D; 3.30.379.10; -; 1.
DR   InterPro; IPR025705; Beta_hexosaminidase_sua/sub.
DR   InterPro; IPR015883; Glyco_hydro_20_cat.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR029018; Hex-like_dom2.
DR   InterPro; IPR029019; HEX_eukaryotic_N.
DR   Pfam; PF00728; Glyco_hydro_20; 1.
DR   Pfam; PF14845; Glycohydro_20b2; 1.
DR   PIRSF; PIRSF001093; B-hxosamndse_ab_euk; 1.
DR   PRINTS; PR00738; GLHYDRLASE20.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   SUPFAM; SSF55545; SSF55545; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Gangliosidosis; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Neurodegeneration; Reference proteome; Signal;
KW   Zymogen.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000269|PubMed:2952641,
FT                   ECO:0000305|PubMed:11707436"
FT   PROPEP          23..88
FT                   /evidence="ECO:0000269|PubMed:2965147"
FT                   /id="PRO_0000011993"
FT   CHAIN           89..529
FT                   /note="Beta-hexosaminidase subunit alpha"
FT                   /id="PRO_0000011994"
FT   REGION          423..424
FT                   /note="Critical for hydrolysis GM2 gangliosides"
FT   ACT_SITE        323
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        115
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1533633,
FT                   ECO:0000269|PubMed:16698036, ECO:0000305|PubMed:11707436"
FT   CARBOHYD        157
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1533633,
FT                   ECO:0000269|PubMed:16698036, ECO:0000269|PubMed:19159218,
FT                   ECO:0000305|PubMed:11707436"
FT   CARBOHYD        295
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1533633,
FT                   ECO:0000269|PubMed:16698036, ECO:0000269|PubMed:19159218,
FT                   ECO:0000305|PubMed:11707436"
FT   DISULFID        58..104
FT                   /evidence="ECO:0000269|PubMed:16698036,
FT                   ECO:0000305|PubMed:11707436"
FT   DISULFID        277..328
FT                   /evidence="ECO:0000269|PubMed:16698036,
FT                   ECO:0000305|PubMed:11707436"
FT   DISULFID        505..522
FT                   /evidence="ECO:0000269|PubMed:16698036,
FT                   ECO:0000305|PubMed:11707436"
FT   VAR_SEQ         1..192
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056657"
FT   VAR_SEQ         359..360
FT                   /note="LL -> YP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056658"
FT   VAR_SEQ         361..529
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056659"
FT   VARIANT         25
FT                   /note="P -> S (in GM2G1; late infantile)"
FT                   /evidence="ECO:0000269|PubMed:8445615"
FT                   /id="VAR_003202"
FT   VARIANT         39
FT                   /note="L -> R (in GM2G1; infantile; dbSNP:rs121907979)"
FT                   /id="VAR_003203"
FT   VARIANT         114
FT                   /note="E -> K (in GM2G1; unknown pathological significance;
FT                   dbSNP:rs748190164)"
FT                   /evidence="ECO:0000269|PubMed:22723944"
FT                   /id="VAR_077497"
FT   VARIANT         127
FT                   /note="L -> F (in GM2G1)"
FT                   /evidence="ECO:0000269|PubMed:9150157"
FT                   /id="VAR_022439"
FT   VARIANT         127
FT                   /note="L -> R (in GM2G1; infantile; dbSNP:rs121907975)"
FT                   /id="VAR_003204"
FT   VARIANT         166
FT                   /note="R -> G (in GM2G1; late infantile)"
FT                   /evidence="ECO:0000269|PubMed:8581357"
FT                   /id="VAR_003205"
FT   VARIANT         170
FT                   /note="R -> Q (in GM2G1; infantile; inactive or unstable
FT                   protein; dbSNP:rs121907957)"
FT                   /evidence="ECO:0000269|PubMed:9338583"
FT                   /id="VAR_003206"
FT   VARIANT         170
FT                   /note="R -> W (in GM2G1; infantile; dbSNP:rs121907972)"
FT                   /evidence="ECO:0000269|PubMed:1302612,
FT                   ECO:0000269|PubMed:22723944"
FT                   /id="VAR_003207"
FT   VARIANT         178
FT                   /note="R -> C (in GM2G1; infantile; inactive protein;
FT                   dbSNP:rs121907953)"
FT                   /id="VAR_003208"
FT   VARIANT         178
FT                   /note="R -> H (in GM2G1; infantile; inactive protein;
FT                   dbSNP:rs28941770)"
FT                   /id="VAR_003209"
FT   VARIANT         178
FT                   /note="R -> L (in GM2G1; infantile; dbSNP:rs28941770)"
FT                   /id="VAR_003210"
FT   VARIANT         180
FT                   /note="Y -> H (in GM2G1; dbSNP:rs28941771)"
FT                   /evidence="ECO:0000269|PubMed:8757036"
FT                   /id="VAR_003211"
FT   VARIANT         192
FT                   /note="V -> L (in GM2G1; infantile; dbSNP:rs387906310)"
FT                   /id="VAR_003212"
FT   VARIANT         196
FT                   /note="N -> S (in GM2G1; dbSNP:rs753862880)"
FT                   /evidence="ECO:0000269|PubMed:7717398"
FT                   /id="VAR_003213"
FT   VARIANT         197
FT                   /note="K -> T (in GM2G1; dbSNP:rs121907973)"
FT                   /id="VAR_003214"
FT   VARIANT         200
FT                   /note="V -> M (in GM2G1; dbSNP:rs1800429)"
FT                   /id="VAR_003215"
FT   VARIANT         204
FT                   /note="H -> R (in GM2G1; infantile; dbSNP:rs121907976)"
FT                   /id="VAR_003216"
FT   VARIANT         210
FT                   /note="S -> F (in GM2G1; infantile; dbSNP:rs121907961)"
FT                   /evidence="ECO:0000269|PubMed:1837283"
FT                   /id="VAR_003217"
FT   VARIANT         211
FT                   /note="F -> S (in GM2G1; infantile; dbSNP:rs121907974)"
FT                   /id="VAR_003218"
FT   VARIANT         226
FT                   /note="S -> F (in GM2G1; dbSNP:rs769866128)"
FT                   /evidence="ECO:0000269|PubMed:9150157"
FT                   /id="VAR_022440"
FT   VARIANT         247
FT                   /note="R -> W (in HEXA pseudodeficiency;
FT                   dbSNP:rs121907970)"
FT                   /evidence="ECO:0000269|PubMed:1384323"
FT                   /id="VAR_003219"
FT   VARIANT         249
FT                   /note="R -> W (in HEXA pseudodeficiency;
FT                   dbSNP:rs138058578)"
FT                   /evidence="ECO:0000269|PubMed:17974005,
FT                   ECO:0000269|PubMed:7902672"
FT                   /id="VAR_003220"
FT   VARIANT         250
FT                   /note="G -> D (in GM2G1; juvenile; dbSNP:rs121907959)"
FT                   /evidence="ECO:0000269|PubMed:1301189"
FT                   /id="VAR_003221"
FT   VARIANT         250
FT                   /note="G -> S (in GM2G1; dbSNP:rs1057521137)"
FT                   /evidence="ECO:0000269|PubMed:7717398"
FT                   /id="VAR_003222"
FT   VARIANT         252
FT                   /note="R -> H (in GM2G1; dbSNP:rs762255098)"
FT                   /id="VAR_003223"
FT   VARIANT         252
FT                   /note="R -> L (in GM2G1)"
FT                   /evidence="ECO:0000269|PubMed:14566483"
FT                   /id="VAR_017188"
FT   VARIANT         258
FT                   /note="D -> H (in GM2G1; infantile; dbSNP:rs121907971)"
FT                   /evidence="ECO:0000269|PubMed:1302612"
FT                   /id="VAR_003224"
FT   VARIANT         269
FT                   /note="G -> D (in GM2G1; dbSNP:rs121907980)"
FT                   /evidence="ECO:0000269|PubMed:9150157"
FT                   /id="VAR_022441"
FT   VARIANT         269
FT                   /note="G -> S (in GM2G1; late onset; inhibited subunit
FT                   dissociation; loss of processing to a mature form;
FT                   increased degradation; dbSNP:rs121907954)"
FT                   /evidence="ECO:0000269|PubMed:2522679,
FT                   ECO:0000269|PubMed:27682588"
FT                   /id="VAR_003225"
FT   VARIANT         279
FT                   /note="S -> P (in GM2G1; late infantile)"
FT                   /evidence="ECO:0000269|PubMed:9401008"
FT                   /id="VAR_003226"
FT   VARIANT         293
FT                   /note="S -> I (in dbSNP:rs1054374)"
FT                   /id="VAR_058477"
FT   VARIANT         295
FT                   /note="N -> S (in GM2G1; dbSNP:rs199578185)"
FT                   /evidence="ECO:0000269|PubMed:14566483"
FT                   /id="VAR_017189"
FT   VARIANT         301
FT                   /note="M -> R (in GM2G1; infantile; dbSNP:rs121907977)"
FT                   /id="VAR_003227"
FT   VARIANT         304
FT                   /note="Missing (in GM2G1; infantile; Moroccan Jewish;
FT                   dbSNP:rs121907960)"
FT                   /evidence="ECO:0000269|PubMed:9338583"
FT                   /id="VAR_003228"
FT   VARIANT         314
FT                   /note="D -> V (in GM2G1; dbSNP:rs1555472696)"
FT                   /evidence="ECO:0000269|PubMed:9150157"
FT                   /id="VAR_022442"
FT   VARIANT         320
FT                   /note="Missing (in GM2G1; late infantile;
FT                   dbSNP:rs797044434)"
FT                   /evidence="ECO:0000269|PubMed:1532289"
FT                   /id="VAR_003229"
FT   VARIANT         322
FT                   /note="D -> N (in GM2G1; dbSNP:rs772180415)"
FT                   /evidence="ECO:0000269|PubMed:22723944"
FT                   /id="VAR_077498"
FT   VARIANT         322
FT                   /note="D -> Y (in GM2G1; dbSNP:rs772180415)"
FT                   /evidence="ECO:0000269|PubMed:22723944"
FT                   /id="VAR_077499"
FT   VARIANT         335
FT                   /note="I -> F (in GM2G1; dbSNP:rs1555472604)"
FT                   /evidence="ECO:0000269|PubMed:7951261"
FT                   /id="VAR_003230"
FT   VARIANT         347..352
FT                   /note="Missing (in GM2G1)"
FT                   /evidence="ECO:0000269|PubMed:7951261"
FT                   /id="VAR_003231"
FT   VARIANT         391
FT                   /note="V -> M (in GM2G1; mild; associated with spinal
FT                   muscular atrophy)"
FT                   /evidence="ECO:0000269|PubMed:7898712"
FT                   /id="VAR_003232"
FT   VARIANT         393
FT                   /note="R -> P (in GM2G1; dbSNP:rs370266293)"
FT                   /evidence="ECO:0000269|PubMed:22723944"
FT                   /id="VAR_077500"
FT   VARIANT         399
FT                   /note="N -> D (in dbSNP:rs1800430)"
FT                   /evidence="ECO:0000269|PubMed:1532289"
FT                   /id="VAR_003233"
FT   VARIANT         420
FT                   /note="W -> C (in GM2G1; infantile; inactive protein;
FT                   dbSNP:rs121907958)"
FT                   /evidence="ECO:0000269|PubMed:14566483,
FT                   ECO:0000269|PubMed:2144098"
FT                   /id="VAR_003234"
FT   VARIANT         436
FT                   /note="I -> V (in dbSNP:rs1800431)"
FT                   /evidence="ECO:0000269|PubMed:1532289,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005,
FT                   ECO:0000269|PubMed:1833974, ECO:0000269|PubMed:2933746,
FT                   ECO:0000269|PubMed:2952641, ECO:0000269|PubMed:3013851,
FT                   ECO:0000269|Ref.5, ECO:0007744|PubMed:21269460"
FT                   /id="VAR_003235"
FT   VARIANT         454
FT                   /note="G -> S (in GM2G1; infantile; dbSNP:rs121907978)"
FT                   /id="VAR_003236"
FT   VARIANT         455
FT                   /note="G -> R (in GM2G1; late infantile)"
FT                   /evidence="ECO:0000269|PubMed:9375850"
FT                   /id="VAR_003237"
FT   VARIANT         458
FT                   /note="C -> Y (in GM2G1; infantile)"
FT                   /evidence="ECO:0000269|PubMed:7837766"
FT                   /id="VAR_003238"
FT   VARIANT         462
FT                   /note="E -> V (in GM2G1; dbSNP:rs863225434)"
FT                   /evidence="ECO:0000269|PubMed:22723944"
FT                   /id="VAR_077501"
FT   VARIANT         474
FT                   /note="W -> C (in GM2G1; subacute; dbSNP:rs121907981)"
FT                   /evidence="ECO:0000269|PubMed:9603435"
FT                   /id="VAR_003239"
FT   VARIANT         478
FT                   /note="G -> R (in GM2G1; dbSNP:rs1057519467)"
FT                   /evidence="ECO:0000269|PubMed:22723944"
FT                   /id="VAR_077502"
FT   VARIANT         482
FT                   /note="E -> K (in GM2G1; infantile; loss of processing to a
FT                   mature form; increased degradation; dbSNP:rs121907952)"
FT                   /evidence="ECO:0000269|PubMed:27682588,
FT                   ECO:0000269|PubMed:2970528, ECO:0000269|PubMed:9338583"
FT                   /id="VAR_003240"
FT   VARIANT         484
FT                   /note="L -> Q (in GM2G1; infantile)"
FT                   /evidence="ECO:0000269|PubMed:7837766"
FT                   /id="VAR_003241"
FT   VARIANT         485
FT                   /note="W -> R (in GM2G1; infantile; dbSNP:rs121907968)"
FT                   /evidence="ECO:0000269|PubMed:1301190"
FT                   /id="VAR_003242"
FT   VARIANT         499
FT                   /note="R -> C (in GM2G1; infantile; dbSNP:rs121907966)"
FT                   /evidence="ECO:0000269|PubMed:14566483"
FT                   /id="VAR_003243"
FT   VARIANT         499
FT                   /note="R -> H (in GM2G1; juvenile; dbSNP:rs121907956)"
FT                   /evidence="ECO:0000269|PubMed:14566483"
FT                   /id="VAR_003244"
FT   VARIANT         504
FT                   /note="R -> C (in GM2G1; infantile; dbSNP:rs28942071)"
FT                   /evidence="ECO:0000269|PubMed:1837283"
FT                   /id="VAR_003245"
FT   VARIANT         504
FT                   /note="R -> H (in GM2G1; juvenile; fails to associate with
FT                   the beta-subunit to form the enzymatically active
FT                   heterodimer; dbSNP:rs121907955)"
FT                   /evidence="ECO:0000269|PubMed:2140574"
FT                   /id="VAR_003246"
FT   MUTAGEN         115
FT                   /note="N->Q: No change of the catalytic activity associated
FT                   with the alpha-chain. No catalytic activity associated with
FT                   the alpha-chain; when associated with Q-157 and Q-295."
FT                   /evidence="ECO:0000269|PubMed:1533633"
FT   MUTAGEN         157
FT                   /note="N->Q: No change of the catalytic activity associated
FT                   with the alpha-chain. No catalytic activity associated with
FT                   the alpha-chain; when associated with Q-115 and Q-295."
FT                   /evidence="ECO:0000269|PubMed:1533633"
FT   MUTAGEN         295
FT                   /note="N->Q: No change of the catalytic activity associated
FT                   with the alpha-chain. No catalytic activity associated with
FT                   the alpha-chain; when associated with Q-115 and Q-157."
FT                   /evidence="ECO:0000269|PubMed:1533633"
FT   CONFLICT        331
FT                   /note="S -> P (in Ref. 5; BAD96222)"
FT                   /evidence="ECO:0000305"
FT   STRAND          28..31
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          36..39
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   TURN            41..43
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          45..48
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           59..73
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          93..100
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          104..106
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          116..123
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          125..131
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           132..145
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          146..148
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          154..157
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          159..163
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          168..175
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   TURN            176..178
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           183..195
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          200..204
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          216..218
FT                   /evidence="ECO:0007744|PDB:2GK1"
FT   HELIX           220..225
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          226..228
FT                   /evidence="ECO:0007744|PDB:2GK1"
FT   TURN            229..231
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           236..248
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          252..256
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          260..262
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   TURN            264..269
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          274..290
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           295..311
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          314..318
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           327..331
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           333..341
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           349..364
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   TURN            365..367
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          369..373
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           374..378
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          388..391
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          394..398
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           400..409
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          413..416
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          426..428
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           431..436
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           446..449
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          452..459
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   TURN            466..468
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           469..473
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           476..485
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   HELIX           493..509
FT                   /evidence="ECO:0007744|PDB:2GJX"
FT   STRAND          517..519
FT                   /evidence="ECO:0007744|PDB:2GJX"
SQ   SEQUENCE   529 AA;  60703 MW;  DACB3E3992E57A47 CRC64;
     MTSSRLWFSL LLAAAFAGRA TALWPWPQNF QTSDQRYVLY PNNFQFQYDV SSAAQPGCSV
     LDEAFQRYRD LLFGSGSWPR PYLTGKRHTL EKNVLVVSVV TPGCNQLPTL ESVENYTLTI
     NDDQCLLLSE TVWGALRGLE TFSQLVWKSA EGTFFINKTE IEDFPRFPHR GLLLDTSRHY
     LPLSSILDTL DVMAYNKLNV FHWHLVDDPS FPYESFTFPE LMRKGSYNPV THIYTAQDVK
     EVIEYARLRG IRVLAEFDTP GHTLSWGPGI PGLLTPCYSG SEPSGTFGPV NPSLNNTYEF
     MSTFFLEVSS VFPDFYLHLG GDEVDFTCWK SNPEIQDFMR KKGFGEDFKQ LESFYIQTLL
     DIVSSYGKGY VVWQEVFDNK VKIQPDTIIQ VWREDIPVNY MKELELVTKA GFRALLSAPW
     YLNRISYGPD WKDFYIVEPL AFEGTPEQKA LVIGGEACMW GEYVDNTNLV PRLWPRAGAV
     AERLWSNKLT SDLTFAYERL SHFRCELLRR GVQAQPLNVG FCEQEFEQT
//
